PubMed Health⌕ Search

Biomedical subjects

Michael D Weil

Publications and source records attributed to Michael D Weil.

2 recordsLinked to original sources

Radiochromic film dosimetry of contrast-enhanced radiotherapy (CERT).

Contrast-enhanced radiotherapy (CERT) employs elevated concentrations of high-Z contrast media in targets to dramatically increase the absorbed dose of radiation relative to the surrounding tissues. However, it is difficult to measure the dose enhancement with routine clinical instruments because the photoelectrons and Auger electrons produced by the interaction of kilovoltage x-rays with the contrast agent travel extremely short distances. We have developed a technique utilizing unlaminated radiochromic film to measure the maximum dose enhancement factor attainable in solutions of contrast agent with iodine concentrations ranging from 0% to 37% (w/v). The films were also used to simultaneously measure the dose enhancement and beam attenuation through solutions containing 0%, 5% and 10% iodine (w/v). These depth-dose measurements were made in phantoms representing 3 cm targets located 0 and 4.8 cm deep in acrylic. Higher concentrations of contrast yielded greater dose enhancement and target-to-surface dose ratios, but caused more rapid attenuation of the beam as it traversed the target. The dose distribution across the entire target could be improved by employing multiple beams. These results, using concentrations of contrast that are clinically achievable by intratumoural injection, illustrate the potential of CERT for the specific delivery of high doses of radiation to targets at depth.

Body Burden↗

Primitive neuroectodermal tumors/medulloblastoma.

The therapy for medulloblastoma/primitive neuroectodermal tumors of the central nervous system is surgery, followed by combination chemo-radiotherapy. The radiation field is the entire craniospinal axis, which is only avoided when treating infants. The treatment is, therefore, lengthy and toxic. Less aggressive therapy is given to patients who clinically appear to have less evidence of disease. Intensive basic research has begun to identify genetic factors of the disease, but these remain far from clinical application.

Brain Neoplasms↗